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Background
The mechanisms involved in the etiology of adverse drug
reactions (ADRs) are complex. A small proportion of
ADRs are due to drug hypersensitivity where the immune
response causes an unexpected and severe clinical reac-
tion. The mechanisms of drug hypersensitivity are not yet
fully understood, but genome wide screens have identified
an association with HLA alleles and certain drugs.
Furthermore, functional studies have identified drug-
responsive T-cells in blood and tissues of hypersensitive
patients. Thus, the frequency and severity of a reaction is a
function of the chemistry of the drug, the biology of the
immune cell and the genotype of the individual.
Method
We sought to establish a biobank of lymphocytes isolated
from HLA-typed volunteers to investigate how drugs and
their metabolites become antigens and interact with the
HLA molecules and T cells to generate an immune
response. We have recruited 900 volunteers so far and
400 of these have been HLA typed.
Results
The typed cohort is representative of the North-West
population and consists of 64% female and 36% male
volunteers with a mean age of 29 years (+/-10 years, range
18-60 years). The ethnicity is primarily Caucasian (84%);
however, a special effort was made to include other ethni-
cities (Asian Indian 6%, Chinese 4%, Black 1%, Other 5%)
in order to increase the HLA allelic diversity within the
cohort. All major Caucasian haplotypes are represented.
Using a DC priming assay we have investigated whether
we could prime naïve T cells to various drugs. Nitroso
sulfamethoxazole was included in all assays as a positive
control and drug-specific proliferative responses were
generated from 35 out of 38 donors. Strong responses
were also generated to carbamazepine in two HLA-B*1502
donors (n=2), to flucloxacillin in one HLA-B*5701 donor
(n=5), to pipericillin in 5 donors (n=10) and to
Bandrowski’s base in all donors (n=7). In contrast, no posi-
tive responses were detected to ximelagatran in four
HLA-DRB1*0701 donors and to lumiracoxib in four
HLA-DRB1*1501 donors. However, drug-specific T cell
clones could still be isolated from 3 donors when only
weak responses to flucloxacillin were detected.
Conclusion
This work shows that drug specific responses can be
generated from naïve T cells and suggests that not all
hypersensitivity reactions are due to cross-reactivity with
existing memory cells.
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